Product Pipeline

BRIM primarily focuses on the process from preclinical to clinical proof of concept (PoC) during the drug development value chain. BRIM primarily targets highly novel projects with new molecular entities (NME) and niche technology platforms, in-licensing them from or partnering with academic institutions and biotech or pharma companies, both locally and internationally. Projects are selected based on their novelty as a drug target or platform technology for diseases where there are unmet medical needs.

An internal integrated management team consisting of project management professionals and translational science experts manage and oversee the specific projects. They provide input and lead all operational activities while sourcing study activities to external entities such research institutes, CROs, and CMOs.

Upon reaching the clinical PoC, BRIM will out-license or partner with the best-suited third party to continue development through market approvals and commercialization, maximizing profit through royalty, milestones, or profit sharing.

All drug development activities are executed according to global regulatory requirements and standards. Clinical trials are conducted to meet requirements for IND submissions to US FDA, CROs, CMOs, CDMOs, and partnership networks (e.g. hospitals, KOLs, government-sponsored agencies, research institutes, CROs & CMOs, etc.). All aspects are fully utilized to accelerate project progress while achieving high quality standards.

BRM421 (Moderate to Severe Dry Eye Syndrome)
Clinical Phase II/III
BRM423 (Severe Corneal Damage)
Clinical Phase II
BRM521 (Osteoarthritis)
Pre-clinical